Celltrion announces positive results for its cocktail therapy candidates including neutralisation data against Omicron variant

Celltrion Group announced today results for its cocktail therapy candidates including neutralisation data against the Omicron variant (B.1.1.529). The Phase I clinical trial is a randomised, double- blind and placebo- controlled trial designed to evaluate the safety, tolerability and pharmacokinetics of CT-P63 in 24 healthy subjects in Poland.1 The study met its primary objectives with data showing CT-P63 to be safe and well tolerated, with no significant drug- related adverse events (AEs).

Related Keywords

South Korea ,Poland ,Incheon ,Inch On Gwangyoksi ,Donna Curran ,National Institutes Of Health ,European Medicines Agency ,Celltrion Group ,Committee For Medicinal Products Human Use ,Marketing Division At Celltrion Healthcare ,National Institutes ,Houng Kim ,Marketing Division ,Medicinal Products ,Human Use ,Celltrion Healthcare ,Media Contact ,Celltrion ,R Houng Kim ,Cocktail Therapy ,Eutralisation Data ,Omicron Variant ,Lobal Phase I ,Ct P63 ,X Ray Crystallography ,Structural Analysis ,Trong Neutralising ,Seudo Virus Testing ,Regkirona ,Ebulised Cocktail Therapy ,Pharmacokinetics ,Yes ,Nih ,Neutralising Antibodies ,Ovid Home Treatment ,